EXECUTIVE SUMMARY

RNAnalytics is a technology-driven company focused on improving the analysis of lipid nanoparticles (LNPs), which are essential for RNA and gene therapies. Their goal is to bring structure and standardization to complex lab workflows by offering modular toolkits and a cloud-based software platform. These toolkits include validated lab protocols, reagents, and reference materials that work with existing lab equipment—making it easier for labs to adopt without major investments. The software automatically analyzes data, generates regulatory-ready reports, and integrates with existing lab systems. RNAnalytics supports startups, research labs, and pharmaceutical companies by making LNP analysis more precise, scalable, and compliant with international standards.

Goal

The goal of the RNAnalytics project was to prepare the company for a successful market launch and its next venture capital funding round. To achieve this, the project focused on three core objectives: conducting a rigorous financial analysis to understand the company’s current financial position and future needs, developing a refined pricing strategy based on customer and market insights, and creating a targeted strategy for engaging with suitable venture capital firms. These efforts aimed to strengthen RNAnalytics’ financial foundation, validate its business model, and enhance its attractiveness to investors through structured, data-driven deliverables and strategic recommendations.

Methodology

The project used a mixed-method approach combining primary and secondary research. Primary research involved interviews with potential clients, experts (such as scientists) and Venture Capital investors to gather insights on pricing, value perception, and market needs. Secondary research supported this by analyzing industry reports, financial data, and internal documents to validate cost structures and identify suitable venture capital firms. Together, these methods informed a refined pricing strategy, a solid financial analysis, and a targeted investor engagement plan.

Results

The project delivered a comprehensive strategic package to support RNAnalytics in preparing for a strong market entry and upcoming venture capital funding. Key outcomes included a fully developed financial model in Excel, offering a detailed view of the company’s current financial status and future projections. A competitor and USP analysis helped position RNAnalytics clearly within the biotech analytics landscape. Based on customer insights and market research, a concrete pricing strategy and market entry plan were developed to align with real-world demand and maximize revenue potential. Additionally, the team created a venture capital roadmap, including key performance indicators (KPIs) that investors typically look for. These KPIs were evaluated, and RNAnalytics received tailored recommendations on how to improve in these areas. 

As a bonus, the team compiled a list of 60 relevant venture capital firms in the DACH region, providing a strong foundation for targeted investor outreach.

Cooperation Partner

• RNAAnalytics Advanced Research GmbH

• Sindelarstraße 1/1, 3040, Neulengbach, Austria

• www.rnanalytics.eu/de/Startseite/
   

Contact Person

• Enkmann, Viktoria  - venkmann@rnanalytics.eu

• Burgstaller, Hannes - hburgstaller@rnanalytics.eu

Student Team

• Ferraris, Nicolas

• Kurtulmus, Melih

• Pieringer, Lisa-Marie

• Poprady, Levente

• Pribernig, Michael

• Pribernig, Andreas

• Raab, Leo

Project Manager

• Horvath, Dorothee 

• Monsorno, Benjamin